130 related articles for article (PubMed ID: 26223483)
1. Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature.
Hamdeh S; Upadhyay S; Khanal N; Lanspa S
J Gastrointest Cancer; 2016 Dec; 47(4):420-422. PubMed ID: 26223483
[No Abstract] [Full Text] [Related]
2. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
[No Abstract] [Full Text] [Related]
3. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
4. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
[No Abstract] [Full Text] [Related]
5. Perforating folliculitis-like reaction related to sorafenib.
Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
[No Abstract] [Full Text] [Related]
6. Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
Okada K; Nakano Y; Yamasaki K; Nitani C; Fujisaki H; Hara J
Cancer Med; 2016 Aug; 5(8):1947-9. PubMed ID: 27264843
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib (Nexavar) for thyroid cancer.
Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
[No Abstract] [Full Text] [Related]
8. Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.
Sammons SL; Pratz KW; Smith BD; Karp JE; Emadi A
Am J Hematol; 2014 Sep; 89(9):936-8. PubMed ID: 24898801
[No Abstract] [Full Text] [Related]
9. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
10. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
11. Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.
Kosmider O; Chapuis N; Kaltenbach S; Coriat R; Boudou Rouquette P; Willems L; Chesnais V; Radford-Weiss I; Bardet V; Mayeux P; Tamburini J; Fontenay M; Bouscary D
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):347-50. PubMed ID: 23246161
[No Abstract] [Full Text] [Related]
12. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
13. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
[TBL] [Abstract][Full Text] [Related]
14. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
15. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
Xu L; Wang B; Ding W
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
[No Abstract] [Full Text] [Related]
16. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
[No Abstract] [Full Text] [Related]
17. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Kashima T; Ohno Y; Tachibana M
Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
[No Abstract] [Full Text] [Related]
18. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
[No Abstract] [Full Text] [Related]
19. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
[No Abstract] [Full Text] [Related]
20. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]